Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Armata Pharmaceuticals, Inc.APHB · Entity 6329 | Chief Operating Officer | May 30, 2017 | June 01, 2017 |
| IOVANCE BIOTHERAPEUTICS, INC.IOVA · Entity 2090 | Chief Operating Officer | September 08, 2026 | September 10, 2026 |
| Oncternal Therapeutics, Inc.ONCT · Entity 89585 | Chief Business Officer | February 11, 2021 | February 16, 2021 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Armata Pharmaceuticals, Inc.
Report date May 30, 2017 · Filed June 01, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.74 · Expires 2027-05-29 | Direct | 87,161 |
Reported balance
After 2017-05-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-05-30 · Grant · Acquired 87,161 · Balance 87,161 F1: 1/4th of the shares subject to the option vest on May 30, 2018. The remainder of the shares vest in equal monthly installments thereafter over the next three years. |
Filing footnotes · ownership attribution and instrument terms
F1: 1/4th of the shares subject to the option vest on May 30, 2018. The remainder of the shares vest in equal monthly installments thereafter over the next three years.
IOVANCE BIOTHERAPEUTICS, INC.
Report date September 08, 2026 · Filed September 10, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 146,050 |
Reported balance
After 2026-09-08 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2026-09-08 · Exercise / conversion · Acquired 7,813 · Balance 146,050 F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. |
| Common StockSEC Table I · non-derivative | Direct | 142,074 |
Reported balance
After 2026-09-08 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2026-09-08 · Tax withholding · Disposed 3,976 · Balance 142,074 F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3: Represents common stock remaining after deducting the common stock withheld for taxes. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 46,878 |
Reported balance
After 2026-09-08 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-08 · Exercise / conversion · Disposed 7,813 · Balance 46,878 F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5: The remaining RSUs will vest in equal quarterly installments. F6: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date.
F2: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities.
F3: Represents common stock remaining after deducting the common stock withheld for taxes.
F4: Each RSU represents a contingent right to receive one share of the Issuer's common stock.
F5: The remaining RSUs will vest in equal quarterly installments.
F6: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person.
Oncternal Therapeutics, Inc.
Report date February 11, 2021 · Filed February 16, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $7.05 · Expires 2031-02-11 | Direct | 130,000 |
Reported balance
After 2021-02-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-02-11 · Grant · Acquired 130,000 · Balance 130,000 F1: One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-fourth (1/4th) of the shares subject to the stock options shall vest on first anniversary of the date of grant, and the remaining shares subject to the option shall vest in thirty-six (36) equal monthly installments over the three-year period thereafter, subject to the Reporting Person's continued employment or service with the Issuer on each such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 08, 2026 Filed Sep 10, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 7,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-106750 · tm2625111-2_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,878 Underlying: Common stock · 7,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 3,976 | $8.70 | $34,591.20 |
DisclosureSEC source: 0001104659-26-106750 · tm2625111-2_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,074 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 7,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-106750 · tm2625111-2_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 146,050 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 8,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-105099 · tm2624648-1_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,580 Underlying: Common stock · 8,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 4,472 | $8.28 | $37,028.16 |
DisclosureSEC source: 0001104659-26-105099 · tm2624648-1_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 138,237 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 01, 2026 Filed Sep 3, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 8,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-105099 · tm2624648-1_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,709 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 7,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071891 · tm2617137-1_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 54,691 Underlying: Common stock · 7,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 3,976 | $4.23 | $16,818.48 |
DisclosureSEC source: 0001104659-26-071891 · tm2617137-1_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 133,920 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 05, 2026 Filed Jun 9, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 7,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-071891 · tm2617137-1_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 137,896 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 8,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-070149 · tm2616710-1_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,369 Underlying: Common stock · 8,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 4,473 | $3.96 | $17,713.08 |
DisclosureSEC source: 0001104659-26-070149 · tm2616710-1_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 130,083 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 01, 2026 Filed Jun 3, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 8,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-070149 · tm2616710-1_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 134,556 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 21:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 117,500 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-026442 · tm268453-1_4seq1.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 117,500 Underlying: Common stock · 117,500 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 31,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-024759 · tm268187-1_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,504 Underlying: Common stock · 31,246 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 5, 2025, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 16,628 | $4.58 | $76,156.24 |
DisclosureSEC source: 0001104659-26-024759 · tm268187-1_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 125,766 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 05, 2026 Filed Mar 6, 2026 22:00 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 31,246 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-024759 · tm268187-1_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 142,394 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,517 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023538 · tm267902-3_4seq1.xml · derivative · entry 4 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 3,517 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 8,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023538 · tm267902-3_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 35,159 Underlying: Common stock · 8,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 6,903 | $3.79 | $26,162.37 |
DisclosureSEC source: 0001104659-26-023538 · tm267902-3_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 111,148 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 02, 2026 Filed Mar 4, 2026 22:01 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 12,307 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-26-023538 · tm267902-3_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 118,051 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 22:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-118169 · tm2532666-3_4seq1.xml · derivative · entry 6 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,517 Underlying: Common stock · 3,516 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 22:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,786 | $2.14 | $3,822.04 |
DisclosureSEC source: 0001104659-25-118169 · tm2532666-3_4seq1.xml · nonDerivative · entry 4 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,744 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| December 02, 2025 Filed Dec 3, 2025 22:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-118169 · tm2532666-3_4seq1.xml · nonDerivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 107,530 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 8,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-118169 · tm2532666-3_4seq1.xml · derivative · entry 5 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 43,949 Underlying: Common stock · 8,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 4,464 | $2.23 | $9,954.72 |
DisclosureSEC source: 0001104659-25-118169 · tm2532666-3_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 104,014 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| December 01, 2025 Filed Dec 3, 2025 22:02 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 8,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-118169 · tm2532666-3_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 8,790 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-087545 · tm2525186-1_4seq1.xml · derivative · entry 4 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 52,738 Underlying: Common stock · 8,790 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-087545 · tm2525186-1_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,033 Underlying: Common stock · 3,516 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 6,250 | $2.19 | $13,687.50 |
DisclosureSEC source: 0001104659-25-087545 · tm2525186-1_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,689 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| September 02, 2025 Filed Sep 4, 2025 22:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 12,306 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-087545 · tm2525186-1_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 105,939 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:47 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 8,789 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056437 · tm2517077-2_4seq1.xml · derivative · entry 4 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,528 Underlying: Common stock · 8,789 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:47 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056437 · tm2517077-2_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,549 Underlying: Common stock · 3,516 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:47 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 6,250 | $1.76 | $11,000.00 |
DisclosureSEC source: 0001104659-25-056437 · tm2517077-2_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,633 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| June 02, 2025 Filed Jun 4, 2025 20:47 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 12,305 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-056437 · tm2517077-2_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 99,883 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| March 05, 2025 Filed Mar 8, 2025 01:05 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | GrantRestricted Stock Units · Derivative | 93,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021868 · tm258333-7_4seq1.xml · derivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,750 Underlying: Common stock · 93,750 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock. F2 · derivative.exercise_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. F2 · derivative.expiration_date: Provided the Reporting Person is still employed with the Issuer on the following dates, the RSUs shall vest over three years, with (i) one-third of the RSUs vesting on the one-year anniversary of the date of grant and (ii) the remaining RSUs shall vest in eight equal quarterly installments over the next two years, commencing with the first quarter following the first anniversary of the date of grant. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:32 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 58,590 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021058 · tm258333-4_4seq1.xml · derivative · entry 4 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 70,317 Underlying: Common stock · 58,590 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F7 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:32 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021058 · tm258333-4_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,065 Underlying: Common stock · 3,516 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:32 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 33,302 | $4.04 | $134,540.08 |
DisclosureSEC source: 0001104659-25-021058 · tm258333-4_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 87,578 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| March 03, 2025 Filed Mar 6, 2025 01:32 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 62,106 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-021058 · tm258333-4_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 120,880 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 22:59 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004202 · tm253469-1_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common stock · 2,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on January 14, 2022, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 22:59 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,578 | $5.89 | $9,294.42 |
DisclosureSEC source: 0001104659-25-004202 · tm253469-1_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 58,774 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| January 14, 2025 Filed Jan 16, 2025 22:59 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-25-004202 · tm253469-1_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 60,352 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-125544 · tm2430163-2_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,581 Underlying: Common stock · 3,516 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,784 | $9.07 | $16,180.88 |
DisclosureSEC source: 0001104659-24-125544 · tm2430163-2_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,539 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| December 02, 2024 Filed Dec 4, 2024 21:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-125544 · tm2430163-2_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 59,323 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 22:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-109272 · tm2426276-1_4seq1.xml · derivative · entry 3 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,813 Underlying: Common stock · 2,813 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on January 14, 2022, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 22:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Tax withholdingCommon Stock | 1,428 | $9.77 | $13,951.56 |
DisclosureSEC source: 0001104659-24-109272 · tm2426276-1_4seq1.xml · nonDerivative · entry 2 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 55,807 F2 · security: Represents shares withheld by the Issuer to satisfy the mandatory tax withholding requirements upon vesting of the RSUs. This is not an open market sale of securities. F3 · balance_after: Represents common stock remaining after deducting the common stock withheld for taxes. Read SEC document |
| October 14, 2024 Filed Oct 16, 2024 22:30 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionCommon Stock | 2,813 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-109272 · tm2426276-1_4seq1.xml · nonDerivative · entry 1 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,235 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Represents such shares underlying the restricted stock units ("RSUs") which vested on the transaction date. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:53 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 23,438 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097488 · tm2423453-2_4seq1.xml · derivative · entry 6 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,437 Underlying: Common Stock · 23,438 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F7 · derivative.exercise_date: The remaining RSUs will vest on the one-year anniversary of the initial grant date, as provided in footnote 8. F7 · derivative.expiration_date: The remaining RSUs will vest on the one-year anniversary of the initial grant date, as provided in footnote 8. F8 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 1, 2024, but does not include any other RSUs held by such Reporting Person. Read SEC document |
| September 03, 2024 Filed Sep 5, 2024 23:53 UTC | IOVANCE BIOTHERAPEUTICS, INC. IOVA · Entity 2090 | Exercise / conversionRestricted Stock Units · Derivative | 3,516 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-097488 · tm2423453-2_4seq1.xml · derivative · entry 5 BILINSKY IGOR · CIK 0001594604 · Chief Operating Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,097 Underlying: Common stock · 3,516 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of the Issuer's common stock. F5 · derivative.exercise_date: The remaining RSUs will vest in equal quarterly installments. F5 · derivative.expiration_date: The remaining RSUs will vest in equal quarterly installments. F6 · balance_after: Such aggregate number reflects the remainder of such RSUs granted on March 2, 2023, but does not include any other RSUs held by such Reporting Person. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.